

FOCUS_{ON} PHARMA



CREATING
PROTECTING
& ENFORCING
High-Value IP Assets

OCTOBER 25, 2019

Conference

9:00 a.m. - 4:45 p.m.

Reception

4:45 - 6:00 p.m.

Wireless Network: SKGF-Guest
Password: ipChallenge



PROGRAM AGENDA

FRIDAY, OCTOBER 25

8:30 a.m. - 4:00 p.m. Conference Check-in Throughout the Day

8:30 - 9:00 a.m. Continental Breakfast

9:00 a.m. Welcoming Remarks

Michael B. Ray, Managing Director, **Sterne, Kessler, Goldstein & Fox**

9:05 a.m. Conference Overview

Paul A. Ainsworth, Director and Conference Co-Chair

9:10 a.m. Five Cases Likely to Have a Big Impact on Life Sciences IP (Presentation)

Director Jorge A. Goldstein, Ph.D. will highlight five important cases to watch and consider. He will frame each case and discuss the implications for life science companies' IP.

Featuring:

- Jorge A. Goldstein, Ph.D., Director, **Sterne, Kessler, Goldstein & Fox**

PROGRAM AGENDA

9:45 a.m.

Patenting Downstream Inventions (Presentation)

This presentation will cover the findings of Sterne Kessler's research into how downstream pharma and biopharma patents fare at the PTAB. Director Eric K. Steffe will highlight lessons from PTAB decisions and implications for prosecution and portfolio strategy.

Featuring:

- Eric K. Steffe, Director, **Sterne, Kessler, Goldstein & Fox**

10:15 a.m.

Morning Break

10:30 a.m.

Global Patent Portfolio Strategies (Panel Discussion)

This panel will highlight ideas and solutions that enable pharma IP teams to align patent portfolios with R&D, acquisition, and product strategies. This discussion will touch on strategies that are appropriate for companies at different developmental levels, domestically and globally.

Featuring:

- Constance Yeung, Vice President, IP Region Head, **Takeda Pharmaceutical Company Limited**
- Cara Lowen, Vice President & Chief Patent Counsel, **Codiak BioSciences**
- Matthew P. Blischak, Vice President, Intellectual Property Counsel, **Roivant Sciences**
- Mita Mukherjee, Senior Patent Director, **AstraZeneca/MedImmune**
- Paul A. Calvo, Ph.D., Director, **Sterne, Kessler, Goldstein & Fox**
- **Moderator:** Marsha Rose Gillentine, Ph.D., Director, **Sterne, Kessler, Goldstein & Fox**

PROGRAM AGENDA

11:15 a.m.

ANDA at 35 (Panel Discussion)

The 35th anniversary of the passage of the Hatch-Waxman Act provides a historic touch point for a discussion of trends in ANDA litigation. Perspectives of both branded and generic pharmaceutical companies will be represented, along with insights from Sterne Kessler directors.

Featuring:

- Daniel Forchheimer, Associate General Counsel North America IP Litigation, **Teva Pharmaceutical Industries Ltd.**
- Liza M. Walsh, Partner, **Walsh Pizzi O'Reilly Falanga LLP**
- Kirsten Braun, Senior Counsel, Global Oncology, **AstraZeneca**
- Deirdre M. Wells, Director, **Sterne, Kessler, Goldstein & Fox**
- **Moderator:** J.C. Rozendaal, Director, **Sterne, Kessler, Goldstein & Fox**

12:00 p.m.

Lunch Buffet & Networking

12:30 p.m.

Keynote Luncheon Speaker

Featuring:

Henry Hadad, Senior Vice President and Deputy General Counsel, **Bristol-Myers Squibb Company** and President, Board of Directors, **Intellectual Property Owners Association**

1:15 p.m.

Roundtable Breakout Sessions

- Ethics in IP Law (Ethics CLE)
- Trademarks and Brand Protection in Life Sciences
- Crisis and Critical Communications (led by LEVICK)
- A Friendly Competition at the Sterne Kessler Barista Bar

Featuring:

- Richard Levick, Chairman & CEO, **LEVICK**
- Jorge A. Goldstein, Ph.D., Director, **Sterne, Kessler, Goldstein & Fox**
- Elham Dehbozorgi, General Counsel, **Sterne, Kessler, Goldstein & Fox**
- Monica Riva Talley, Director, **Sterne, Kessler, Goldstein & Fox**

PROGRAM AGENDA

2:15 p.m.

While You Were Working: PTAB Developments You May Have Missed

This fast-paced presentation will cover a range of updates from the PTAB with emphasis on life science IPRs. The presentation will also spotlight the implications PTAB developments have for patent prosecution and litigation.

Featuring:

- Eldora L. Ellison, Ph.D., Director, **Sterne, Kessler, Goldstein & Fox**
- Deborah Sterling, Ph.D., Director, **Sterne, Kessler, Goldstein & Fox**

2:45 p.m.

Afternoon Break

3:00 p.m.

Biosimilar Development: Dialog From Diverse Perspectives

IP strategies for both branded and biosimilar companies will be discussed, 10 years after the passage of BPCIA. This discussion will look at factors that will affect the availability of biosimilars in the future (e.g. litigation, molecule complexity, manufacturing processes, pricing, interchangeability, and approved indications).

Featuring:

- Paul Golian, Vice President & Assistant General Counsel, **Bristol-Myers Squibb Company**
- Chandrika Vira, Director, **Sterne, Kessler, Goldstein & Fox**
- **Moderator:** Timothy J. Shea, Jr., Director, **Sterne, Kessler, Goldstein & Fox**

3:45 p.m.

Legal Challenges for Emerging Technologies in the Life Sciences

This panel will discuss overcoming challenges associated with protecting emerging technologies, building on perspectives on several exciting new areas, including:

- Gene Therapy and Diagnostics
- CRISPR and Gene Editing
- Microbiome
- Cell Therapy

Featuring:

- Christopher Verni, Vice President & Chief Intellectual Property Counsel, **Sarepta Therapeutics, Inc.**
- Kimya Harris, Vice President, Head of Intellectual Property and Legal Affairs, **KSQ Therapeutics, Inc.**
- Chang B. Hong, Executive Director, Head of IP, **Synlogic, Inc.**
- Minako Pazdera, Vice President, Intellectual Property, **Lyell Immunopharma**
- **Moderator:** Carla Ji-Eun Kim, Director, **Sterne, Kessler, Goldstein & Fox**

4:45 p.m.

Wrap-Up and Take Away Lessons

- Paul A. Ainsworth, Director and Conference Co-Chair
- Eldora L. Ellison, Ph.D., Director and Conference Co-Chair

4:45 - 6:00 p.m.

Closing Reception